Polymorphism of gene promotor region for MMP-2 in rheumatoid arthritis
Authors:
P. Němec 1,2; M. Goldbergová 2; T. Swobodnik 2; D. Polášková 2; M. Souček 1; A. Vašků 2
Authors‘ workplace:
Revmatologická ambulance II. interní kliniky Lékařské fakulty MU a FN u sv. Anny, Brno, přednosta doc. MUDr. Miroslav Souček, CSc.
1; Ústav patologické fyziologie Lékařská fakulty MU, Brno, přednostka prof. MUDr. Anna Vašků, CSc.
2
Published in:
Vnitř Lék 2006; 52(4): 348-354
Category:
Original Contributions
Overview
Introduction:
Matrix metalloproteinase (MMP) belonging to family of zinc-dependent endopeptidases participates in remodelling of extracellular matrix in many physiological and pathological processes including rheumatoid arthritis (RA). Rheumatoid arthritis is a chronic autoimmune inflammatory multi-systemic disease characterized, among others, by degradation of hyaline articular cartilage and escalated angiogenesis. As a matter of fact, these processes may by influenced by MMP. On the other hand, MMP can suppress inflammation by degrading biologically active molecules like cytokines, chemokines or growth factor receptors. Increased levels of MMP-2 (gelatinase A) are observed in serum and synovial fluid of patients with RA. Gene polymorphism for MMP-2 can affect susceptibility to development and/or severity of RA.
Method:
The aim of the study was to prove possible association of polymorphisms in gene promotor region for MMP-2 (–1575 G/A, –1306 C/T, –790 T/G, –735 C/T) with RA. We worked with 101 patients with RA who met reviewed diagnostic criteria of ACR (1987) for RA, and suffer from RA for at least 2 years. Control group consisted of 101 healthy volunteers of similar age and gender distribution.
Results:
RA patients and control group did not differ in genotype distributions or frequencies of alleles of polymorphisms –1575A/G, –1306C/T and –735 C/T. Significant difference was observed between RA patients and control group in allelic frequencies of polymorphism –790 T/G MMP-2 (T allele –0.70 vs. 0.66, Pa = 0.013). Also, a tendency of GG genotype growth was noted in RA patients (Pg = 0.053). Significant difference in allelic frequencies was also observed between men with RA and men from control group (T allele –0.80 vs. 0.61, Pa = 0.025). Haplotype of GCGC polymorphisms –1575 G/A, –1306 C/T, –790 T/G, –735 C/T was more frequent in RA patients (Pcorr = 0.016; OR = 0.09; confidence interval 0.00–0.65), whereas GCTC haplotype was noted more frequently in control group (Pcorr = 0.017; OR = 1.8; confidence interval 1.17–2.70).
Conclusion:
The results indicate the association between polymorphisms in gene promotor region for MMP-2 and susceptibility to development of RA.
Key words:
Rheumatoid arthritis – gene – polymorphism – MMP-2
Sources
1. Harney SM, Newton JL, Worsworth BP. Molecular genetics of rheumatoid arthritis. Curr Opin Pharmacol 2003; 3: 280-285.
2. Lawrence RC, Helmick GG, Arnett FC et al. Estimates of the prevalence of arthritis and selected musculosceletal disorders in the United States. Arthritis Rheum 1998; 41: 778-799.
3. Goldring SR. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology (Oxford) 2003; 42(Suppl 2): ii11-ii16.
4. Yamada H, Yoshihara Y. Mechanism of cartilage destruction in rheumatoid arthritis. Clin Calcium 2003; 13: 702-708.
5. Hembry RM, Bagga MR, Reynolds JJ et al. Immunolocalization studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis. Ann Rheum Dis 1995; 54: 25-32.
6. Okada Y, Takeuchi N, Tomita K et al. Immunolocalization of matrix metalloproteinase 3 (stromelysin) in rheumatoid synovioblasts (B cell): correlation with rheumatoid arthritis. Ann Rheum Dis 1989; 48: 645-653.
7. Okada Y, Gonoji Y, Nakanishi I et al. Immunohistochemical demonstration of collagenase and tissue inhibitor of metalloproteinases (TIMP) in synovial lining cells of rheumatoid synovium. Virch Arch B Cell Pathol 1990; 59: 305-312.
8. Grillet B, Dequeker J, Paemen L et al. Gelatinase B in synovitis: immunolocalization with a monoclonal antibody. Br J Rheumatol 1997; 36: 744-747.
9. Ahrens D, Koch AE, Pope RM et al. Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum 1996; 39: 1576-1587.
10. Stephenson ML, Goldring MB, Birkhead JR et al. Stimulation of procollagenase synthesis parallels increases in cellular procollagenase mRNA in human articular chondrocytes exposed to recombinant interleukin-1β. Biochem Biophys Res Commun 1987; 144: 583-590.
11. Okada Y, Shinmei M, Tanaka O et al. Localization of matrix metalloproteinase 3 (stromelysin) in osteoarthritic cartilage and synovium. Lab Invest 1992; 66: 680-690.
12. Cole AA, Chubinskaya S, Schumacher B et al. Chondrocyte matrix metalloproteinase-8. Human articular chondrocytes express neutrophil collagenase. J Biol Chem 1996; 271: 11023-11026.
13. Mohtai M, Smith RL, Schurman DJ et al. Expression of 92-kDa type IV collagenase/gelatinase (gelatinase B) in osteoarthritic cartilage and its induction in normal human articular cartilage by interleukin 1. J Clin Invest 1993; 92: 179-185.
14. Walakovits LA, Moore VL, Bhardwaj N et al. Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury. Arthritis Rheum 1992; 35: 35-42.
15. Clark IM, Powell LK, Ramsey S et al. The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP), and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 1993; 36: 372-379.
16. Yoshihara Y, Obata K, Fujimoto N et al. Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in serum from patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 969-975.
17. Shinmei M, Kobayashi T, Yoshihara Y et al. Significance of the levels of carboxy terminal type II procollagen peptide, chondroitin sulfate isomers, tissue inhibitor of metalloproteinases, and metalloproteinases in osteoarthritis joint fluid. J Rheumatol 1995; 22(Suppl 43): 78-81.
18. Matsuki H, Fujimoto N, Iwata K et al. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 8 (neutrophil collagenase) using monoclonal antibodies. Clin Chim Acta 1996; 244: 129-143.
19. Sopata I, Wize J, Filipowicz-Sosnowska A et al. Neutrophil gelatinase levels in plasma and synovial fluid of patients with rheumatic diseases. Rheumatol Int 1995; 15: 9-14.
20. Yoshihara Y, Nakamura H, Obata K et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 2000; 59: 455-461.
21. Nagase H, Woessner JF. Matrix Metalloproteinases. J Biol. Chem 1999; 274: 21491-21494.
22. Itoh T, Matsuda H, Tanioka M et al. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J Immunol 2002; 169: 2643-2647.
23. Ito A, Mukaiyama A, Itoh Y et al. Degradation of interleukin 1 beta by matrix metalloproteinases. J Biol Chem 1996; 271: 14657-14660.
24. McQuibban GA, Gong JH, Tam EM et al. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant-3. Science 2000; 289: 1202-1206.
25. Levi E, Fridman R, Miao HQ et al. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Acad Sci USA 1996; 93: 7069-7074.
26. Cawley LJ, Matrisian LM. Matrix metalloproteinases: they´re not just for matrix anymore! Curr Opin Cell Biol 2001; 13: 534-540.
27. Aho K, Koskenvuo M, Tuominen J et al. Occurrence of rheumatoid arthritis in a nationwide series of twin. J Rheumatol 1986; 13: 899-902.
28. MacGregor AJ, Snieder H, Rigby AS et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000; 43: 30-37.
29. Winchester R. The molecular basis of susceptibility to rheumatoid arthritis. Adv Immunol 1994; 56: 389-466.
30. Gregersen PK. Genetics of rheumatoid arthritis: confronting complexity. Arthritis Res 1999; 1: 37-44.
31. Seldin MF, Amos CI, Ward R et al. The genetics revolution and the assault on rheumatoid arthritis. Arthritis Rheum 1999; 42: 1071-1079.
32. Singal DP, Li J, Lei K. Genetics of rheumatoid arthritis (RA): two separate regions in the major histocompatibility complex contribute to susceptibility to RA. Immunol Letters 1999; 69: 301-306.
33. Winchester R. The molecular basis of susceptibility to rheumatoid arthritis. Adv Immunol 1994; 56: 398-466.
34. Rowley MJ, Stockman A, Brand CA et al. The effect of HLA-DRB1 disease susceptibility markers on the expression of RA. Scand J Rheumatol 1997; 26: 448-455.
35. Vencovský J, Pešáková V, Kafková J et al. Přínos některých laboratorních vyšetření k diagnostice a hodnocení revmatoidní artritidy. Čes Revmatol 1999; 7: 155-165.
36. Yamada R, Tanaka T, Ohnishi Y et al. Identification of 142 single nucleotide polymorphisms in 41 candidate genes for rheumatoid arthritis in the Japanese population. Hum Genet 2000; 106: 293-297.
37. Halushka MK, Fan JB, Bentley K et al. Patterns of single nucleotide polymorphisms in candidate genes of blood-presure homeostasis. Nat Genet 1999; 22: 239-247.
38. Sato H, Takino T, Okada Y et al. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 1994; 370: 61-65.
39. Takino T, Sato H, Shinagawa A et al. Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library. MT-MMPs form a unique membrane-type subclass in the MMP family. J Biol Chem 1995; 270: 23013-23020.
40. Will H, Hinzmann B. cDNA sequence and mRNA tissue distribution of novel human matrix metalloproteinase with a potential transmembrane segment. Eur J Biochem 1995; 231: 602-608.
41. Puente XS, Pendás AM, Liano E et al. Molecular cloning of novel membrane-type matrix metalloproteinase from a human breast carcinoma. Cancer Res 1996; 56: 944-949.
42. Pei D. Identification and characterization of the fifth membrane-type matrix metalloproteinase MT5-MMP. J Biol Chem 1999; 274: 8925-8932.
43. Pendas AM, Knäuper V, Puente XS et al. Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution. J Biol Chem 1997; 272: 4281-4286.
44. Bartlett JD, Simmer JP, Xue J et al. Molecular cloning and mRNA tissue distribution of a novel matrix metalloproteinase isolated from porcine enamel organ. Gene 1996; 183: 123-128.
45. Velasco G, Pendas AM, Fueyo A et al. Cloning and characterization of human MMP-23, a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members. J Biol Chem 1999; 274: 4570-4576.
46. Uría JA, Ferrando AA, Velasco G et al. Structure and expression in breast tumors of human TIMP-3, a new member of the metalloproteinase inhibitor family. Cancer Res 1994; 54: 2091-2094.
47. Greene J, Wang M, Liu YE et al. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem 1996; 271: 30375-30380.
48. Nagase H, Okada Y. Proteinases and matrix degradation. In: Kelly WN, Harris ED Jr, Ruddy S et al (eds). The text book of rheumatology. 5th ed. Philadelphia: WB Saunders 1996; 323-341.
49. Jovanovic DV, Martel-Pelletier J, Di Battista JA et al. Stimulation of 92-kd gelatinase (matrix metalloproteinase 9) production by interleukin-17 in human monocyte/macrophages: a possible role in rheumatoid arthritis. Arthritis Rheum 2000; 43: 1134-1144.
50. Dörr S, Lechtenböhmer N, Rau R et al. Association of a specific haplotype across the genes MMP1 nd MMP-3 with radiographic joint destruction in rheumatoid arthritis. Arthritis Res Ther 2004; 6: R199-R207.
51. Constantin A, Lauwers-Cances V, Navaux F et al. Collagenase-1 (MMP-1) and HLA-DRB1 gene polymorphisms in rheumatoid arthritis: a prospective longitudinal study. J Rheumatol 2002; 29: 15-20.
52. Constantin A, Lauwers-Cances V, Navaux F et al. Stromelysin 1 (matrix metalloproteinase 3) and HLA-DRB1 gene polymorphisms: association with severity and progression of rheumatoid arthritis in a prospective study. Arthritis Rheum 2002; 46: 1754-1762.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2006 Issue 4
Most read in this issue
- Medical videothoracoscopy in diagnosis and therapy of pleural effusions
- Primary prevention of ischemic heart disease in middle-aged men living in Prague: Results of twenty-year research
- The Prophylaxis against Venous Thromboembolic Complications in Internal Medicine - the Gap between Theory and Practice
- Ubiquitins, proteasomes, sumoylation and application today and in future for cancer and other diseases therapy I. Ubiquitin-proteasome system and the transcription factor NF-κB